• Information

    Informazioni per i medici

    È possibile accedere qui alla documentazione sul consensus delle linee guida cliniche attuali. (linee guida attuali / palliazione) Lo pseudomixoma peritoneale (PMP) è una malattia rara con un indice di incidenza di circa 2 persone per milione. Durante la tua carriere potresti diagnosticare al massimo uno o due pazienti affetti da questa malattia. Spesso è difficile la diagnosi differenziale tra lo PMP e un più comune tipo di tumore mucinoso, come il cancro ovarico, senza l’ausilio di un profondo esame istologico condotto da un patologo esperto. Lo PMP è una neoplasia mucinosa ad ampia diffusione che si verifica nella cavità peritoneale e, generalmente, originato da un tumore appendicolare che porta…

  • Research

    New Review Examines Current Research Strategies

    Researchers Christin Lund-Andersen, Annette Torgunrud, Karianne Giller-Fleten (shared first-authors) and P.I. Kjersti Flatmark have published an extensive review article looking at the use of high-throughput -omics analysis in the search for a cure for peritoneal metastases from colorectal cancer (PM-CRC) and pseudomyxoma peritonei (PMP). The study looked at molecular approaches including genomic, transcriptomic and proteomic analyses, and tumour enrichment strategies to determine whether there are any patterns in the data that could potentially assist in the management of patients with PM-CRC or PMP. The findings indicate that while there are many potential areas to focus on in the research environment, there is a strong indication that the best way forward…

  • Events

    Proceedings of the EuroPMP Pathology Workshop

    Held the 10th December 2020 Chair: Professor Norman Carr Panel members: Drs Robert Bradley, Søren Krag, and Melissa Taggart. Presenters: Drs Peggy Dartigues, Marie-Louise (Loes) van Velthuysen, Wiebke Solass, Frédéric Bibeau, and Bipasha Chakrabarty. 

  • Events

    Workshop on the Pathology of PMP – 10th December 2020

    EuroPMP will present a workshop on the pathology of PMP on 10th December 2020. The proceedings of the workshop will be available to view online following the workshop. The workshop is being presented by Dr Norman Carr and will run from 17:00-18:45 GMT (18:00-19:45 CET). Please check your email for more information. Before the meeting, you may wish to read more about the pathology of PMP to get acquainted with the terminology and histology of the disease. Dr Carr has prepared a short primer on the topic, which you can access at this link. The programme for the workshop can be accessed here. To view a recording of the workshop,…

  • Research

    New study looks at efficacy of Neoadjuvant Intraperitoneal Chemotherapy in Unresectable PMP Patients

    EuroPMP member Andreas Brandl has recently, in collaboration with Yutaka Yonemura, published a new paper looking into the efficacy of neoadjuvant intraperitoneal chemotherapy in patients who were not candidates for cytoreductive surgery at the time of diagnosis. The study showed low morbidity and mortality when neoadjuvant intraperitoneal chemotherapy was given to patients, and appears to show a higher rate of complete cytoreduction compared to the traditional treatment afforded these patients. The study is still ongoing and will report on the long-term survival characteristics of these and more patients in the future. The new paper may be read here.

  • Research

    New Paper from Finland – Altered linkage pattern of N-glycan sialic acids in PMP

    All human cells are covered by sugar coating, mostly consisting of glycan structures attached to proteins and lipids, and this coating frequently shows alterations in tumor cells. In their new publication, Finland’s Pirjo Nummela, Anna Lepistö and Ari Ristimäki have analyzed the profiles of a specific class of glycans, sialylated N-glycans, in PMP tissues compared to both normal appendices and the original appendix tumors (LAMNs). According to their results, PMPs present increased expression of glycans able to function as ligands of Siglecs and selectins, which may play a role in the peritoneal dissemination and progression of the disease. Further, the glycan profiles of PMPs suggest that the process of its…

  • Research

    Incidence and Prevalence in Europe

    EuroPMP member researchers from Norway and the United Kingdom have recently published a paper giving a sound scientific footing for the incidence and prevalence of PMP in Europe. The research suggests that the previous incidence estimate of 1-2 persons per million is too low, with a more realistic figure being around 3.2 persons per million. The prevalence was estimated to be around 22 persons per million in Europe, meaning 11,726 people living with active disease in 2018. The incidence and prevalence paper can be read here.  

  • News

    The Effects of COVID-19 on PMP Services Around Europe

    Around the world, the COVID-19 epidemic has been hitting our health care systems very hard. Intensive care units have been inundated with patients requiring careful, around-the-clock care. Physicians have been transferred from their normal duties to hastily set up critical care wards within their districts to try to treat the vast numbers of affected patients. Nurses have been sent out to test patients in temporary drive-up clinics, and biologists and lab workers have had their normal duties re-directed to include testing the enormous numbers of patient samples incoming daily from worried patients. We have heard much about the effects on primary care physicians and clinical specialists, but we have not…

  • Research

    Individual Efficacy of Drug Therapies in Xenograft Models

    Norway’s Karianne Giller Fleten, Christin Lund-Andersen, Annette Torgunrud and Kjersti Flatmark have published a new paper that looks into the individual efficacy of four drug therapies on peritoneal metastases in mouse-human xenograft models: oxaliplatin, irinotecan, cabazitaxel, and regorafenib and capecitabine. The results support the continued exploration of intraperitoneal treatment protocols for peritoneal metastases with oxaliplatin remaining and cabazitaxel emerging as the most interesting candidates for further studies. You can read the new paper here.

  • News

    PSOGI/EURACAN Clinical Practice Guidelines

    A new consensus paper undertaking a complex and thorough investigation into current clinical practice has been released by an international group including many members of EuroPMP. As pseudomyxoma peritonei (PMP) is such a rare disease, it is difficult to find large, randomised trials on which to base treatment decisions. Therefore, using the Delphi consensus model, the Peritoneal Surface Oncology Group International (PSOGI) Executive Committe, which includes may members of EuroPMP, have examined and recommended a new and current best practice for the diagnosis and treatment of PMP. The Delphi decision model was used in conjunction with a broad literature review to come to this agreement, which will now form a…